TMG's EBITDA grows to $103.3m in FY23

Its Singapore segment revenue was driven by higher bill sizes.

SGX-listed Thomson Medical Group (TMG) posted a EBITDA of $355.8m for FY 2023, higher than $109.7m in FY 2022 due to lower income project-related services.

It was also cushioned by the reduced government grant, according to its financial report.

The hospital group's net profit after tax was $41.1m in FY 2023 from $58.6m in FY 2022.

TMG's revenue in 2023 went up 6.6% from 2022 as patient count rises and healthcare spending increases.

The hospital segment grew 14.6% whilst in Singapore higher average bill sizes also rose.

"We remain focused on our plans to expand and enhance our medical centres and clinics in Singapore, including a multi-year asset enhancement initiative of our flagship hospital in Singapore," read the statement.

Follow the link for more news on

Thomson Medical

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia